- Home
- NBR vs TRML Comparison
NBR vs TRML Comparison
Compare NBR & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBR
- TRML
- Stock Information
- Founded
- NBR 1952
- TRML 2021
- Country
- NBR Bermuda
- TRML United States
- Employees
- NBR N/A
- TRML N/A
- Industry
- NBR Oil & Gas Production
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- NBR Energy
- TRML Health Care
- Exchange
- NBR Nasdaq
- TRML Nasdaq
- Market Cap
- NBR 633.5M
- TRML 509.8M
- IPO Year
- NBR N/A
- TRML N/A
- Fundamental
- Price
- NBR $42.82
- TRML $13.40
- Analyst Decision
- NBR Hold
- TRML Strong Buy
- Analyst Count
- NBR 7
- TRML 6
- Target Price
- NBR $73.33
- TRML $45.20
- AVG Volume (30 Days)
- NBR 483.9K
- TRML 378.2K
- Earning Date
- NBR 04-23-2025
- TRML 05-12-2025
- Dividend Yield
- NBR N/A
- TRML N/A
- EPS Growth
- NBR N/A
- TRML N/A
- EPS
- NBR N/A
- TRML N/A
- Revenue
- NBR $2,930,126,000.00
- TRML N/A
- Revenue This Year
- NBR $13.54
- TRML $363.93
- Revenue Next Year
- NBR $8.39
- TRML N/A
- P/E Ratio
- NBR N/A
- TRML N/A
- Revenue Growth
- NBR N/A
- TRML N/A
- 52 Week Low
- NBR $34.42
- TRML $11.87
- 52 Week High
- NBR $105.96
- TRML $29.79
- Technical
- Relative Strength Index (RSI)
- NBR 46.99
- TRML 35.48
- Support Level
- NBR $40.08
- TRML $16.39
- Resistance Level
- NBR $45.69
- TRML $17.36
- Average True Range (ATR)
- NBR 2.42
- TRML 1.09
- MACD
- NBR 0.46
- TRML -0.38
- Stochastic Oscillator
- NBR 48.84
- TRML 6.36
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.